The incidence of perioperative @entity532 after XXXX is not increased after neoadjuvant chemoradiotherapy.

@entity1 @entity1149 @entity532 @entity9876 @entity91 @entity850 @entity902
BACKGROUND: Concurrent neoadjuvant chemoradiotherapy can potentially impact on the results of @entity9876 . The purpose of this study was to examine this effect in terms of morbidity, mortality, and long-term survival in @entity1 with @entity1149 . METHODS: Clinical records of @entity1 with @entity1149 undergoing @entity9876 between 1983 and 2008 were reviewed for age, sex, type of sleeve resection, clinicopathologic TNM stage, complications, and 90-day mortality. Chemotherapy and radiation therapy regimens were recorded for the @entity1 undergoing neoadjuvant treatment. Kaplan-Meier survival curves were compared. RESULTS: There were 64 @entity1 identified as having undergone sleeve resection for @entity1149 . Of the 64 total @entity1 , 43 did not receive concurrent neoadjuvant chemoradiotherapy [NCR] versus 21 @entity1 who did [ @entity91 ]. All of the @entity91 @entity1 underwent @entity902 -based chemotherapy and radiation (range, 2,000 to 6,100 cGy). Thirteen @entity1 (62%) were downstaged, with 4 complete responders. The 90-day mortality was 2.7% (2 @entity1 ) in the NCR group and 0% in the @entity91 group. The incidence of major complications in the NCR group was 46.5% (20 of 43) with 4.7% (2 of 43) @entity532 ( @entity850 , 1; bronchovascular fistula, 1). The incidence of major complications in the @entity91 group was 42.9% (9 of 21) with no anastomosis-related problems. Five-year survival in the NCR group was 48% compared with 41% in the @entity91 group (p = 0.63). There were 9% (4 of 43) of @entity1 with local recurrence in the NCR group versus 10% (2 of 21) of @entity1 in the @entity91 group (p = 0.65). CONCLUSIONS: Anastomosis-related complications were not increased among the @entity1 receiving neoadjuvant therapy compared with those who did not. In addition, local recurrence was also similar between the two groups. Furthermore, the survival of the two groups was not statistically different. Sleeve lobectomy after chemoradiotherapy for advanced @entity1149 can be performed with acceptable morbidity and mortality.
